About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

STEMTECH CORPORATION ANNOUNCES LIFE FACTOR RESEARCH BECOMES PART OF STEMTECH

By: via GlobeNewswire

MIRAMAR, FL, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative stemceutical™ company and a pioneer in the field of stem cell nutrition, today announced that it has finalized its acquisition agreement with Life Factor Research, a leading manufacturer in the nutraceutical world.

Stemtech Corporation President and Chief Operating Officer, John W. Meyer, said “we are extremely pleased to announce the finalization of the agreement to add Life Factor Research to the family of Stemtech Corporation businesses as the division responsible for research and development and product formulations. This new arrangement will enable Stemtech to offer more new, cutting-edge products to an ever-growing market interested in improved health and quality of life.”

Charles S. Arnold, Stemtech Corporation Chairman and CEO stated that “our commitment to excellence and being the cutting-edge stemceutical formulator company takes a huge leap forward with the addition of LFR to the Stemtech global enterprise. We will be developing many new products in close consultation with Life Factor Research for improving health benefits, anti-aging and longevity around the globe.”

Charles Layton, CEO of Life Factor Research commented that “from our beginnings, Life Factor Research has held fast to our foundational concept of creating nutraceutical products that through their proprietary nature and scientific proof create lasting change for our clients and their customers. During our progress in the highly expanding anti-aging space, we have had a core desire to align ourselves with the right “strategic partner”, and with great pride and anticipation of what is to come we are most grateful to be able to announce our alignment with Stemtech Corporation. Over the last year our team has had the opportunity to get a deep understanding of Stemtech's core values in the Stem Cell rejuvenation space and at the same time gain an appreciation for the distribution channels that will now be reached as a result of this union.”

Mr. Layton continues that “LFR has aggregated tremendous proprietary compounds, formulations, delivery and absorption technologies as well as patents that will be introduced into the market in truly revolutionary products which will, in some cases, be category creating. As the CEO of Life Factor Research, it would be impossible for me to overstate our collective potential in a space that is experiencing growth at a level which has been exploding year over year.”

About Stemtech Corporation

Stemtech Corporation, a leading stemceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem, OraStem® (Oral Health Care), and D-Fuze™ (EMF blocker). Its stemceutical products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on August 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

www.Stemtech.com

Investor Relations:
Phone: 954-715-6000 ext 1040.
Email: invrel@stemtech.com


Primary Logo

More News

View More
Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet
Via MarketBeat
Topics Economy World Trade
Tickers LVMUY
3 High-Yield Banks for Investors to Buy on the Dip
Via MarketBeat
Tickers FITB USB XLF ZION
5 Surprising Stocks Set to Benefit From a Future Robotics Boom
Via MarketBeat
Topics Artificial Intelligence World Trade
Tickers ALB NUE NVDA QS UUUU
3 Oversold Large-Caps That Look Ripe for a Rebound
Via MarketBeat
Tickers CTAS FAST GEN
Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance?
Via MarketBeat
Tickers GOOGL META

Recent Quotes

View More
Symbol Price Change (%)
AMZN  216.48
+3.44 (1.61%)
AAPL  262.24
+9.95 (3.94%)
AMD  240.56
+7.48 (3.21%)
BAC  52.04
+0.76 (1.48%)
GOOG  257.02
+3.23 (1.27%)
META  732.17
+15.26 (2.13%)
MSFT  516.79
+3.21 (0.63%)
NVDA  182.64
-0.58 (-0.32%)
ORCL  277.18
-14.13 (-4.85%)
TSLA  447.43
+8.12 (1.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.